EichorEICHOR
Study identifier: NCT06743334 Synced from ClinicalTrials.gov · August 02, 2026
● Completed

Secondary Databased Post-marketing Surveillance Study of BNT162b2

Condition: COVID-19 · SARS-CoV-2  ·  Sponsor: Pfizer

PhaseN/A
Planned participants14302529
Who can joinAll sexes, 6 Months to no upper limit
Healthy volunteersNo

About this study

This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

PfizerSeoul, South Korea—

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06743334